PURPOSE: @entity61339 (SKI-2053R, Sunpla ), a new @entity902 analogue which has a better @entity137 profile than @entity900 , has been used with @entity1487 ( @entity1487 ) continuous infusion for the treatment of advanced @entity356 . However, continuous @entity1487 infusion had a inconvenience to administration. The aim of this study was to evaluate the efficacy and @entity137 of @entity61339 , UFT-E and @entity4181 combination chemotherapy in advanced @entity356 . MATERIALS AND METHODS: A total of 22 @entity1 was enrolled in this study at Kyung Hee University and Korea University from September 1999 to May 2001. @entity61339 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/m2 and @entity4181 45 mg/day were administered for 21 consecutive days followed by a 7-day drug free interval. This schedule was repeated every 4 weeks. RESULTS: The 22 enrolled @entity1 received 81 courses of chemotherapy and the median number of course per @entity1 was three with a range of one to six. Five of 21 @entity1 achieved partial responses (23.8%; 95% confidence interval, 5.6% to 42%) without complete response. Out of the 5 responding @entity1 , three had unresectable perigastric lymph-nodes, one @entity1 had a @entity43 , and one @entity1 had a peritoneal @entity3 respectively. Main @entity137 were @entity1398 and @entity390 / @entity391 . Grade 3 and 4 @entity1398 were observed in 4 @entity1 (18%) and grade 3 @entity390 / @entity391 were observed in 5 @entity1 (22.7%). The median time to progression was 4 months (range, 0.5 to 13 months), and median survival duration was 7.5 months (range, 2.0 to 14 months). Median response duration was 5.0 months (range, 1.5 to 10 months). CONCLUSION: A combination chemotherapy of @entity61339 , UFT-E and @entity4181 has a comparable efficacy with those of previously reported @entity61339 and intravenous regimen of @entity1487 and controllable @entity137 in advanced @entity356 . Further study with large @entity1 population is warranted to determine the usefulness of this regimen.

Pilot Study of @entity61339 , UFT-E and @entity4181 in Advanced XXXX .

@entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian metastasis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity61339 :: ('MESH:C090717', 'Chemical') :: ['heptaplatin', 'Heptaplatin'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric carcinoma'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity356 :: (MESH:D013274,Disease) :: ['Gastric Carcinoma']
